These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 11352962)

  • 1. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
    Strother D; Ashley D; Kellie SJ; Patel A; Jones-Wallace D; Thompson S; Heideman R; Benaim E; Krance R; Bowman L; Gajjar A
    J Clin Oncol; 2001 May; 19(10):2696-704. PubMed ID: 11352962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor.
    Sung KW; Yoo KH; Cho EJ; Koo HH; Lim DH; Shin HJ; Ahn SD; Ra YS; Choi ES; Ghim TT
    Pediatr Blood Cancer; 2007 Apr; 48(4):408-15. PubMed ID: 17066462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy.
    Prados MD; Wara W; Edwards MS; Ater J; Rabbit J; Lamborn K; Davis R; Levin VA
    Pediatr Neurosurg; 1996 Oct; 25(4):174-81. PubMed ID: 9293544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive disease in children with medulloblastoma/PNET during preradiation chemotherapy.
    Tornesello A; Mastrangelo S; Piciacchia D; Bembo V; Colosimo C; Di Rocco C; Mastrangelo R
    J Neurooncol; 1999; 45(2):135-40. PubMed ID: 10778729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
    Allen J; Donahue B; Mehta M; Miller DC; Rorke LB; Jakacki R; Robertson P; Sposto R; Holmes E; Vezina G; Muraszko K; Puccetti D; Prados M; Chan KW
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1006-11. PubMed ID: 19356859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors.
    Allen JC; Donahue B; DaRosso R; Nirenberg A
    Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1155-61. PubMed ID: 8985038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
    Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
    Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.
    Fangusaro J; Finlay J; Sposto R; Ji L; Saly M; Zacharoulis S; Asgharzadeh S; Abromowitch M; Olshefski R; Halpern S; Dubowy R; Comito M; Diez B; Kellie S; Hukin J; Rosenblum M; Dunkel I; Miller DC; Allen J; Gardner S
    Pediatr Blood Cancer; 2008 Feb; 50(2):312-8. PubMed ID: 17668858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET.
    Chintagumpala M; Hassall T; Palmer S; Ashley D; Wallace D; Kasow K; Merchant TE; Krasin MJ; Dauser R; Boop F; Krance R; Woo S; Cheuk R; Lau C; Gilbertson R; Gajjar A
    Neuro Oncol; 2009 Feb; 11(1):33-40. PubMed ID: 18796696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
    Pérez-Martínez A; Lassaletta A; González-Vicent M; Sevilla J; Díaz MA; Madero L
    J Neurooncol; 2005 Jan; 71(1):33-8. PubMed ID: 15719272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
    J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
    Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
    J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
    Merchant TE; Kun LE; Krasin MJ; Wallace D; Chintagumpala MM; Woo SY; Ashley DM; Sexton M; Kellie SJ; Ahern V; Gajjar A
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):782-7. PubMed ID: 17892918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy.
    Jennings MT; Cmelak A; Johnson MD; Moots PL; Pais R; Shyr Y
    Pediatr Blood Cancer; 2004 Jul; 43(1):46-54. PubMed ID: 15170889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma.
    Chi SN; Gardner SL; Levy AS; Knopp EA; Miller DC; Wisoff JH; Weiner HL; Finlay JL
    J Clin Oncol; 2004 Dec; 22(24):4881-7. PubMed ID: 15611503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study.
    Prados MD; Edwards MS; Chang SM; Russo C; Davis R; Rabbitt J; Page M; Lamborn K; Wara WM
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):279-85. PubMed ID: 10030250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors.
    Choi LM; Rood B; Kamani N; La Fond D; Packer RJ; Santi MR; Macdonald TJ
    Pediatr Blood Cancer; 2008 May; 50(5):970-5. PubMed ID: 17941070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.
    Massimino M; Gandola L; Spreafico F; Luksch R; Collini P; Giangaspero F; Simonetti F; Casanova M; Cefalo G; Pignoli E; Ferrari A; Terenziani M; Podda M; Meazza C; Polastri D; Poggi G; Ravagnani F; Fossati-Bellani F
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1031-7. PubMed ID: 16343801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy.
    Packer RJ; Sutton LN; Elterman R; Lange B; Goldwein J; Nicholson HS; Mulne L; Boyett J; D'Angio G; Wechsler-Jentzsch K
    J Neurosurg; 1994 Nov; 81(5):690-8. PubMed ID: 7931615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
    Yasuda K; Taguchi H; Sawamura Y; Ikeda J; Aoyama H; Fujieda K; Ishii N; Kashiwamura M; Iwasaki Y; Shirato H
    Jpn J Clin Oncol; 2008 Jul; 38(7):486-92. PubMed ID: 18573848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.